RICHMOND, Va., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) (“In

INDV, IRWD, RLMD, LRMR and CRDL could offer significant upside as biotech sentiment improves, backed

HighTower Advisors LLC acquired a new stake in Indivior PLC (NASDAQ: INDV) during the second quarter

Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Indivior Pharmaceutica

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merge

INDV's proposed Supernus merger could broaden its CNS portfolio, cut costs and reduce reliance on Su

Indivior (NASDAQ:INDV) released second-quarter financial results and hosted an earnings call on Tues

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of [url="]Kahn Swic

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr.,

Barclays analyst Glen Santangelo maintains Indivior Pharmaceuticals (NASDAQ:INDV) with a Overweig

Indivior announces a merger with Supernus to form a CNS-focused biopharma company, tops Q2 earnings

The most oversold health care stocks present a buying opportunity. RSI indicator compares stock stre

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Indivior Pharmaceuticals,

NEW YORK, Aug. 3, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Asso

Supernus Pharmaceuticals (SUPN) has seen its stock rise following the announcement of an all-stock m

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) and Indivior Pharmaceuticals Inc. (NASDAQ:INDV) on Mond

Supernus and Indivior agree to merge in an all-stock deal, targeting $2.2 billion in revenue and $12

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merge

Indivior Pharmaceuticals Inc. (INDV) came out with quarterly earnings of $1.15 per share, beating th

Supernus Pharmaceuticals and Indivior Pharmaceuticals said on Monday they had agreed to an all-stock

Indivior Pharmaceuticals (NASDAQ:INDV) raises FY2026 sales outlook from $1.215 billion-$1.285 billio

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) and Indivior Pharmaceuticals, Inc. (NASDAQ:INDV) today

•   Q2'26 Total Net Revenue of $ 343 Million, Up 14% YoY •   Record Quarterly Total SUBLOCADE® Net R

RICHMOND, Va., July 23, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today

Howard Marks hunts dislocation. His latest Oaktree 13F reveals five common-stock equity positions th

Indivior Pharmaceuticals Inc. (INDV) could be a solid choice for shorter-term investors looking to c

Barclays analyst Glen Santangelo initiates coverage on Indivior Pharmaceuticals (NASDAQ:INDV) wit

Compared to patients adherent to monthly injectable buprenorphine, patients on other MOUD (adherent

Kevin Mahn highlighted the potential impact of the recent tariff noise on the market and advised inv

https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20251205-1480992/1480992_decembe

Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is likely to report quarterly earnings

Shares of Wynn Resorts, Limited (NASDAQ: WYNN) fell sharply on Friday after the company reported thi

Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is expected to report quarterly earnin

Companies Reporting Before The Bell • SES AI (NYSE:SES) is projected to report quarterly earnings a